Kelun-Biotech Secures China Breakthrough Designation for ADC Combo
Event summary
- Kelun-Biotech received Breakthrough Therapy Designation (BTD) in China for sacituzumab tirumotecan (sac-TMT) combined with pembrolizumab for first-line treatment of PD-L1-positive, EGFR-negative, ALK-negative NSCLC.
- The BTD designation expedites the review process for potential marketing authorization in China.
- Clinical trial OptiTROP-Lung05 demonstrated statistically significant improvement in progression-free survival (PFS) and a positive trend in overall survival (OS).
- This marks the fifth BTD granted to sac-TMT, expanding its potential applications across multiple cancer types.
- Sac-TMT is licensed to MSD for all territories outside of Greater China.
The big picture
The BTD designation underscores the growing importance of China as a key market for innovative cancer therapies. Sac-TMT's approval, and the subsequent inclusion on the National Reimbursement Drug List (NRDL), could significantly impact Kelun-Biotech's revenue and market share within the rapidly expanding Chinese oncology market. The combination therapy represents a shift towards more targeted and effective treatments for NSCLC, a disease with a significant unmet need.
What we're watching
- Regulatory Speed
- The expedited review pathway afforded by the BTD designation will be a key indicator of the NMPA's commitment to accelerating innovative cancer therapies, and could set a precedent for future ADC approvals.
- Commercial Execution
- Kelun-Biotech's ability to successfully manufacture and distribute sac-TMT in China, alongside MSD's commercial infrastructure outside of China, will be crucial for realizing the full potential of this combination therapy.
- Clinical Data
- Further clinical data, particularly regarding overall survival (OS) and long-term safety, will be critical to solidify sac-TMT's position in the competitive NSCLC treatment landscape.
Related topics